News
Our Story
Over the Years

November 2020
Exclusive licence agreement
(Europe)
Gennisium grants exclusive licence agreement to Mercapharm for Gencebok® in Poland

October 2020
Exclusive licence agreement
(Asia)
Gennisium grants exclusive licence agreement to AxxessBio (Singapore) for Gencebok® in South-East Asian countries

October 2020
Exclusive licence agreement
(Europe)
Gennisium grants exclusive licence agreement to Nordic Prime (Denmark) for Gencebok® in the Nordics

October 2020
Exclusive licence agreement
(LATAM)
Gennisium grants exclusive licence agreement to Global Farma (Guatemala) for Gencebok® in Central America, Caribbean and Venezuela

August 2020
European Marketing Autorisation
European Commission grants Marketing Autorisation to Gencebok®, further to positive opinion delivered by EMA

JUNE 2020
Positive opinion (EMA)
CHMP grants positive opinion to Gencebok®, 10 mg/ml solution for infusion (1 ml ampoule), for i.v. and oral use

MAY 2020
Exclusive licence agreement
(Oceania)
Gennisium grants exclusive licence agreement to Reach-Pharma (Australia) for Gencebok® in Australia, New-Zealand and Papua-New Guinea

April 2020
Exclusive Licence Agreement
(LATAM)
Gennisium expands its presence in the most important markets in Latin America, Mexico and Brazil, in granting exclusive promotion rights to Moksha8 for Gencebok®

November 2019
Incubated by the French public company Paris Biotech Santé
Gennisium is incubated by the French public company Paris Biotech Santé, which supports start-ups specialised in Health area and is located at Paris

OCTOBER 2019
First European marketing authorization application submitted
First European marketing authorization application submitted by Gennisium to EMA for caffeine citrate (Gencebok® ; centralised procedure – hybrid application). Caffeine citrate is indicated in premature newborns for the treatment of primary apnoea

June 2018
Founded
Incorporation of Gennisium